KHPG's subsidiary injectable KH617 has been approved to conduct clinical trials
I'm LongbridgeAI, I can summarize articles.KHPG's subsidiary Honghe Biotech recently received approval from the National Medical Products Administration to conduct clinical trials for injectable KH617. This drug is used in combination with standard treatment regimens for newly diagnosed glioblastoma. Injectable KH617 is Honghe Biotech's first clinical trial product, and Phase I studies have shown good safety and tolerability, with preliminary observations of positive anti-tumor efficacy signals, potentially providing new treatment options for patients
According to the Zhitong Finance APP, KHPG (002773.SZ) announced that its subsidiary Sichuan Honghe Biotechnology Co., Ltd. (hereinafter referred to as "Honghe Biotechnology") has received the Clinical Trial Approval Notice for Injectable KH617 issued by the National Medical Products Administration. The indication for this drug is: combined treatment of newly diagnosed glioblastoma with standard treatment regimens.
Injectable KH617 is the first product from Honghe Biotechnology's synthetic biology platform to enter clinical trials. It is classified as a Class 1 innovative chemical drug. Phase I clinical studies have shown that Injectable KH617 has good safety and tolerability, and preliminary positive signals of anti-tumor efficacy have been observed, which is expected to provide a new treatment option for glioblastoma patients